Skip to main content
Scientific Reports logoLink to Scientific Reports
. 2022 Mar 10;12:4207. doi: 10.1038/s41598-022-07984-w

Monitoring the impact of COVID-19 in France on cancer care: a differentiated impact

Christine Le Bihan Benjamin 1, Julien-Aymeric Simonnet 2, Mathieu Rocchi 1, Inès Khati 1, Estelle Ménard 3, Emilie Houas-Bernat 2, Jean-Baptiste Méric 4, Philippe-Jean Bousquet 3,5,
PMCID: PMC8908298  PMID: 35273304

Abstract

The COVID-19 pandemic has had a substantial and lasting impact on care provision, particularly in the field of cancer care. National steering has helped monitor the health situation and adapt the provision and organisation of care. Based on data from the French administrative healthcare database (SNDS) on the entire French population (67 million people), screening, diagnostic and therapeutic activity was monitored and compared 2019 on a monthly basis. A noteworthy decline in all activities (with the exception of chemotherapy) was observed during the first lockdown in France. Over the months that followed, this activity returned to normal but did not make up for the shortfall from the first lockdown. Finally, during the lockdown in late 2020, cancer care activity was conserved. In brief, in 2020, the number of mammograms decreased by 10% (− 492,500 procedures), digestive endoscopies by 19% (− 648,500), and cancer-related excision by 6% (− 23,000 surgical procedures). Hospital radiotherapy activity was down 3.8% (− 4400 patients) and that in private practice was down 1.4% (− 1600 patients). Chemotherapy activity increased by 2.2% (7200 patients), however. To summarize, COVID-19 had a very substantial impact during the first lockdown. Safeguarding cancer care activity helped limit this impact over the months that followed, but the situation remains uncertain. Further studies on the medium- and long-term impact on individuals (survival, recurrence, after-effects) will be conducted.

Subject terms: Cancer, Health care, Oncology

Introduction

Since early 2020, the world has been faced with a pandemic caused by SARS-Cov-2. In terms of health, this has resulted in more or less stringent measures, and restrictions up to and including full lockdown. More precisely, France was under lockdown from 17 March to 11 May 2020, with a travel ban, the closure of so-called non-essential retail and businesses and recreational facilities, and extensive remote working. A second lockdown took place from 28 October to 15 December 2020, which was less restrictive than the first (schools stayed open, and a limited number of businesses continued to operate). Following this lockdown, the entire country was placed under curfew. In March 2021, further measures were gradually introduced to supplement the measures in place, starting with some French departments and then extended throughout the country.

In the field of cancer care, some measures were specifically drafted with in particular a number of guidelines and tools being issued for healthcare professionals by the French Ministry for Health and the French National Cancer Institute (INCa), ranging from adaptation of medical practices in crisis situations, to the resumption of activity, along with the prioritisation of cancer patients for vaccination15 https://www.e-cancer.fr/Professionnels-de-sante/Coronavirus-COVID-19). Furthermore, during the first lockdown, invitations for organised screening programmes (breast, colorectal, cervical) were suspended6, and a number of treatments directly linked with cancer care deferred (surgery, cancer-related hospitalisation, etc.). Similar initiatives have been adopted in most Western countries, repositioning screening with regard to risks due to COVID-19 and in the aim of adapting the healthcare system79.

In view of the risk of missing a diagnosis or of prolonging times to treatment for a substantial number of people, the measures in relation to screening were not renewed during subsequent lockdown periods, despite intensive care unit occupancy being on a par with or exceeding usual capacity. Indeed, a number of studies suggest a reduction in survival associated with increased waiting times to undergo screening1012, diagnosis, or treatment1315. This had led the health authorities to propose new strategies, prioritise cancer patients, and take action in the uncertainty.

In this context, the French National Cancer Institute has set up, with support from the French Ministry for Health, a national steering and monitoring committee in concert with major national and regional stakeholders in cancer care and user representatives. It is organised in a regional structure via local and regional steering committees, helping pass on alerts and important information, and report, on a national level, innovative and exemplary organisations along with issues encountered on a regional level.

The Institute has also developed activity monitoring and steering scorecards aimed at national, regional and local stakeholders. They are intended to monitor prevention, screening, and care activity in hospital and non-hospital settings.

The purpose of this study is to present the cancer care activity monitoring and steering scorecards, estimate the impact of the health crisis due to COVID-19, and present the measures adopted to limit their effects.

Methodology

Data source

Several data sources were used. For non-hospital activity, data from the French administrative healthcare database (SNDS), medico-administrative data covering the entire French population16 were used. These data are updated on a monthly basis.

For hospital activity, the study relied on activity data recorded by all French hospital facilities (Medicalised information system programme) for all inpatients and outpatients. Since the pandemic, these data have been updated on a weekly basis. Although they are also found in the SNDS, these data are processed on the secure ATIH (French agency for information on hospital management) due to quicker availability.

Three months after the activity completion date, these two data sources are sufficiently exhaustive for processing purposes.

Data

Activity monitoring concerns the analysis of medical procedures linked with cancer care for diagnosis, screening, or treatment (excision, chemotherapy, radiotherapy). Lines were selected according to the public health policy in France. For diagnosis, the lines of analysis are upper and lower digestive tract endoscopies, bronchial and ENT endoscopies (fibroscopies), prostate biopsies as per the CCAM (Common classification of medical procedures) list.

For screening, the lines are mammograms under the organised breast cancer screening programme or outside this screening programme, faecal blood screening tests for the organised colorectal cancer screening programme, cytological analyses or human papillomavirus detection for organised cervical screening or outside the organised cervical screening programme as per the different lists concerned (CCAM, NABM – list of medical pathology procedures, and NGAP – general list of professional procedures).

For cancer care-related excisions, the lines of analysis concern the 6 categories of cancer sites for which activity is subject to authorisation17 and to minimum activity thresholds in France: digestive tract (stomach, liver, pancreas, colorectal), gynaecological (ovarian), breast, chest, urological, and ENT (ear, nose, throat) and maxillofacial cancers (CCAM). Oesophageal cancers are excluded from digestive tract, chest and ENT cancers, and presented separately for a better understanding. Stays with cancer removal surgery are identified by coding cancer as the main diagnosis and a surgical removal procedure. Thus, only histologically confirmed cancers should be counted.

For chemotherapy, the data used were from hospital admissions specifying a primary diagnostic code Z511 (ICD 10 – International Classification of Diseases); and, for radiotherapy, hospital admissions specifying a primary diagnostic code Z5101 (ICD 10), and private practice CCAM radiation procedures.

Analyses

Monthly comparisons (number and percent) of care consumption for the years 2019 and 2020 were made to account for seasonal factors in care activity.

Ethic

All methods were carried out in accordance with relevant guidelines and regulations. Data were pseudonymized prior to performing analyses Access to SNDS and PMSI data is subject to authorisation from CNIL (French data protection authority)—decree of 26 December 2016 No. 2016–1871.

Results

The study covered the entire French population, i.e. 67 million people, sex-ratio 0,93 and mean age 42,1 years.

Diagnosis, screening (Table 1, Fig. 1)

Table 1.

Diagnosis and screening.

January February March April May June July August September October November December Total
Digestive tract endoscopies
2019 308,959 286,816 308,816 304,647 298,963 289,361 284,372 170,407 290,696 318,586 282,356 253,945 3,397,924
2020 308,279 281,211 174,032 53,294 141,927 262,496 270,006 175,477 294,410 289,393 254,132 244,734 2,749,391
2021 279,495 263,955 286,928 830,378
Difference 2019/2020  − 680  − 5605  − 134,784  − 251,353  − 157,036  − 26,865  − 14,366 5070 3714  − 29,193  − 28,224  − 9211  − 648,533
Percent 2019/2020  − 0.2  − 2.0  − 43.6  − 82.5  − 52.5  − 9.3  − 5.1 3.0 1.3  − 9.2  − 10.0  − 3.6  − 19.1
Difference 2019/2021  − 29,464  − 22,861  − 21,888  − 74,213
Percent 2019 − 2021  − 9.5  − 8.0  − 7.1
Bronchial and ENT endoscopies
2019 107,085 95,901 106,923 103,516 101,351 96,611 98,820 66,621 99,083 106,101 95,484 88,893 1,166,389
2020 104,733 97,579 64,651 28,750 60,831 92,028 85,333 60,821 93,928 87,278 85,568 81,283 942,783
2021 87,914 82,669 94,018 264,601
Difference 2019/2020  − 2352 1678  − 42,272  − 74,766  − 40,520  − 4583  − 13,487  − 5800  − 5155  − 18,823  − 9916  − 7610  − 223,606
Percent 2019/2020  − 2.2 1.7  − 39.5  − 72.2  − 40.0  − 4.7  − 13.6  − 8.7  − 5.2  − 17.7  − 10.4  − 8.6  − 19.2
Difference 2019/2021  − 19,171  − 13,232  − 12,905  − 45,308
Percent 2019–2021  − 17.9  − 13.8  − 12.1
Mammograms
2019 473,347 421,823 461,522 445,034 442,258 423,883 404,342 284,033 449,133 494,668 445,629 386,486 5,132,158
2020 478,150 437,774 254,122 66,597 278,076 455,482 406,343 316,109 504,807 508,138 495,773 438,251 4,639,622
2021 474,674 445,114 523,430 1,443,218
Difference 2019/2020 4803 15,951  − 207,400  − 378,437  − 164,182 31,599 2001 32,076 55,674 13,470 50,144 51,765  − 492,536
Percent 2019/2020 1.0 3.8  − 44.9  − 85.0  − 37.1 7.5 0.5 11.3 12.4 2.7 11.3 13.4  − 9.6
Difference 2019/2021 1327 23,291 61,908 86,526
Percent 2019 − 2021 0.3 5.5 13.4
Colorectal screening
2019 212,938 199,831 200,709 160,751 116,359 92,929 72,041 68,759 139,420 225,007 273,084 240,014 2,001,842
2020 293,675 310,605 206,161 12,976 68,865 169,754 212,947 215,809 325,936 353,617 324,902 305,949 2,801,196
2021 288,421 276,819 406,604 971,844
Difference 2019/2020 80,737 110,774 5452  − 147,775  − 47,494 76,825 140,906 147,050 186,516 128,610 51,818 65,935 799,354
Percent 2019/2020 37.9 55.4 2.7  − 91.9  − 40.8 82.7 195.6 213.9 133.8 57.2 19.0 27.5 39.9
Difference 2019/2021 75,483 76,988 205,895 358,366
Percent 2019 − 2021 35.4 38.5 102.6
Cervix screening (HPV and cytopathology)
2019 411,678 378,100 416,419 399,230 397,281 377,125 370,493 242,953 398,372 424,446 369,701 337,462 4,523,260
2020 410,798 377,973 252,407 80,142 260,984 433,787 366,413 259,785 430,692 414,737 393,093 342,051 4,022,862
2021 369,688 342,946 360,992 1,073,626
Difference 2019/2020  − 880  − 127  − 164,012  − 319,088  − 136,297 56,662  − 4080 16,832 32,320  − 9709 23,392 4589  − 500,398
Percent 2019/2020  − 0.2 0.0  − 39.4  − 79.9  − 34.3 15.0  − 1.1 6.9 8.1  − 2.3 6.3 1.4  − 11.1
Difference 2019/2021  − 41,990  − 35,154  − 55,427  − 132,571
Percent 2019 − 2021  − 10.2  − 9.3  − 13.3
Prostatic biopsies
2019 9562 8447 9075 8810 8675 8247 7826 5120 9099 9004 8102 6853 98,820
2020 10,151 8560 6217 2975 6601 9176 7549 5042 9201 8621 8673 7451 90,217
2021 9390 8251 8989 26,630
Difference 2019/2020 589 113  − 2858  − 5835  − 2074 929  − 277  − 78 102  − 383 571 598  − 8603
Percent 2019/2020 6.2 1.3  − 31.5  − 66.2  − 23.9 11.3  − 3.5  − 1.5 1.1  − 4.3 7.0 8.7  − 8.7
Difference 2019/2021  − 172  − 196  − 86  − 454
Percent 2019 − 2021  − 1.8  − 2.3  − 0.9

Number of screening and diagnostic acts observed are in [bold].

HPV human papilloma viridae.

Figure 1.

Figure 1

Screening and diagnosis trends. (A) Fibroscopies (ear, nose and throat—ENT and lung). (B) Endoscopies (Digestive track). (C) Mammograms. (D) Prostatic biopsies.

Diagnostic and screening activity was substantially impacted by the first lockdown.

For digestive tract endoscopies, the shortfall was − 43.6% (− 134,784 procedures) in March, − 82.5% (− 251,353) in April, − 52.5% (− 157,036) in May, − 9.3% (− 26,865) in June, and − 5.1% (− 14,366) in July. Over the full year, a shortfall of -19.1% (− 648,533) remained.

For mammograms, the shortfall was − 44.9% (− 207,400 procedures) in March, -85% (− 378,437) in April, − 37.1% (− 164,182) in May. Despite there being no further decreases in activity from June, a shortfall of − 9.6% (− 492,536) remained over the full year.

Similar findings were observed for bronchial and ENT fibroscopies and prostate biopsies. An overall increased in colorectal screening and decrease in cervical screening (HPV test and cytopathology) were observed between 2019 and 2020. (see Table 1 and Fig. 1).

Surgery (excision) (Table 2)

Table 2.

Surgery (excision).

January February March April May June July August September October November December Total
Oesophagus
2019 67 90 99 111 108 107 124 93 81 115 90 125 1210
2020 89 83 99 65 65 97 121 66 81 95 87 90 1038
2021 83 80 91 254
Difference 2019/2020 22  − 7 0  − 46  − 43  − 10  − 3  − 27 0  − 20  − 3  − 35  − 172
percent 2019/2020 32.8  − 7.8 0.0  − 41.4  − 39.8  − 9.3  − 2.4  − 29.0 0.0  − 17.4  − 3.3  − 28.0  − 14.2
Difference 2019/2021 16  − 10  − 8  − 2
Percent 2019/2021 23.9  − 11.1  − 8.1
Stomach
2019 252 254 297 270 262 266 296 216 248 312 270 270 3213
2020 244 271 276 193 217 266 278 173 204 261 253 283 2919
2021 232 224 231 687
Difference 2019/2020  − 8 17  − 21  − 77  − 45 0  − 18  − 43  − 44  − 51  − 17 13  − 294
Percent 2019/2020  − 3.2 6.7  − 7.1  − 28.5  − 17.2 0.0  − 6.1  − 19.9  − 17.7  − 16.3  − 6.3 4.8  − 9.2
Difference 2019/2021  − 20  − 30  − 66  − 116
Percent 2019/2021  − 7.9  − 11.8  − 22.2
Liver
2019 544 595 654 618 585 618 605 422 576 667 545 564 6993
2020 517 576 628 450 478 583 577 424 523 596 546 610 6508
2021 502 562 601 1665
Difference 2019/2020  − 27  − 19  − 26  − 168  − 107  − 35  − 28 2  − 53  − 71 1 46  − 485
Percent 2019/2020  − 5.0  − 3.2  − 4.0  − 27.2  − 18.3  − 5.7  − 4.6 0.5  − 9.2  − 10.6 0.2 8.2  − 6.9
Difference 2019/2021  − 42  − 33  − 53  − 128
Percent 2019/2021  − 7.7  − 5.5  − 8.1
Pancreas
2019 280 337 364 381 323 305 371 294 275 347 300 397 3974
2020 308 329 355 248 256 333 389 258 300 362 301 371 3810
2021 265 366 345 976
Difference 2019/2020 28  − 8  − 9  − 133  − 67 28 18  − 36 25 15 1  − 26  − 164
Percent 2019/2020 10.0  − 2.4  − 2.5  − 34.9  − 20.7 9.2 4.9  − 12.2 9.1 4.3 0.3  − 6.5  − 4.1
Difference 2019/2021  − 15 29  − 19  − 5
Percent 2019/2021  − 5.4 8.6  − 5.2
Colon − Rectum
2019 2645 2907 3139 3200 3163 2898 3453 2571 2624 3097 2732 3018 35,447
2020 2509 2794 3344 2298 2225 2580 3032 2529 2672 2912 2839 3138 32,872
2021 2558 2692 2961 8211
difference 2019/2020  − 136  − 113 205  − 902  − 938  − 318  − 421  − 42 48  − 185 107 120  − 2575
percent 2019/2020  − 5.1  − 3.9 6.5  − 28.2  − 29.7  − 11.0  − 12.2  − 1.6 1.8  − 6.0 3.9 4.0  − 7.3
difference 2019/2021  − 87  − 215  − 178  − 480
percent 2019/2021  − 3.3  − 7.4  − 5.7
ENT + Maxillofacial
2019 1968 1836 2109 1956 2069 1896 2062 1545 1908 2071 2002 2026 23,448
2020 2040 1915 1938 1402 1538 1683 1813 1469 1913 1916 1872 1903 21,402
2021 1865 1811 1883 5559
Difference 2019/2020 72 79  − 171  − 554  − 531  − 213  − 249  − 76 5  − 155  − 130  − 123  − 2046
Percent 2019/2020 3.7 4.3  − 8.1  − 28.3  − 25.7  − 11.2  − 12.1  − 4.9 0.3  − 7.5  − 6.5  − 6.1  − 8.7
Difference 2019/2021  − 103  − 25  − 226  − 354
Percent 2019/2021  − 5.2  − 1.4  − 10.7
Thorax (chest)
2019 1290 1332 1554 1448 1562 1385 1536 1029 1426 1531 1320 1303 16,716
2020 1355 1396 1465 1033 1278 1310 1270 1048 1380 1490 1406 1471 15,902
2021 1342 1411 1452 4205
Difference 2019/2020 65 64  − 89  − 415  − 284  − 75  − 266 19  − 46  − 41 86 168  − 814
Percent 2019/2020 5.0 4.8  − 5.7  − 28.7  − 18.2  − 5.4  − 17.3 1.8  − 3.2  − 2.7 6.5 12.9  − 4.9
Difference 2019/2021 52 79  − 102 29
Percent 2019/2021 4.0 5.9  − 6.6
Breast
2019 7036 6178 7025 6314 6845 6551 7103 5261 6270 6645 6309 6162 77,699
2020 7203 6278 7150 5513 4241 5023 6343 5144 6712 6637 6977 6973 74,194
2021 7204 6555 7022 20,781
Difference 2019/2020 167 100 125  − 801  − 2604  − 1528  − 760  − 117 442  − 8 668 811  − 3505
Percent 2019/2020 2.4 1.6 1.8  − 12.7  − 38.0  − 23.3  − 10.7  − 2.2 7.0  − 0.1 10.6 13.2  − 4.5
Difference 2019/2021 168 377  − 3 542
Percent 2019/2021 2.4 6.1 0.0
Ovary
2019 609 631 727 626 672 635 714 484 664 723 626 662 7773
2020 593 642 691 492 549 686 708 576 668 675 644 684 7608
2021 598 671 662 1931
Difference 2019/2020  − 16 11  − 36  − 134  − 123 51  − 6 92 4  − 48 18 22  − 165
Percent 2019/2020  − 2.6 1.7  − 5.0  − 21.4  − 18.3 8.0  − 0.8 19.0 0.6  − 6.6 2.9 3.3  − 2.1
Difference 2019/2021  − 11 40  − 65  − 36
Percent 2019/2021  − 1.8 6.3  − 8.9
Urology
2019 3411 3474 3902 3527 3692 3539 3575 2217 3575 3894 3259 3348 41,413
2020 3594 3575 3546 2644 3408 3520 3147 2088 3449 3646 3689 3622 39,928
2021 3571 3616 3588 10,775
Difference 2019/2020 183 101  − 356  − 883  − 284  − 19  − 428  − 129  − 126  − 248 430 274  − 1485
Percent 2019/2020 5.4 2.9  − 9.1  − 25.0  − 7.7  − 0.5  − 12.0  − 5.8  − 3.5  − 6.4 13.2 8.2  − 3.6
Difference 2019/2021 160 142  − 314  − 12
Percent 2019/2021 4.7 4.1  − 8.0
Overall
2019 32,190 29,650 33,569 30,649 32,358 30,822 32,679 22,249 31,100 33,330 30,707 29,571 368,874
2020 33,000 30,679 30,127 20,370 23,671 28,733 30,346 21,996 31,896 31,456 32,246 31,207 345,727
2021 31,276 29,421 30,906 91,603
Difference 2019/2020 810 1029  − 3442  − 10,279  − 8687  − 2089  − 2333  − 253 796  − 1874 1539 1636  − 23,147
Percent 2019/2020 2.5 3.5  − 10.3  − 33.5  − 26.8  − 6.8  − 7.1  − 1.1 2.6  − 5.6 5.0 5.5  − 6.3
Difference 2019/2021  − 914  − 229  − 2663  − 3806
Percent 2019/2021  − 2.8  − 0.8  − 7.9

Number of excesions observed are in [bold].

For all excisions, the reduction in activity was very substantial, primarily in April, in which the whole month was spent under lockdown, in line with surgical activity cancellation directives. As such, for colorectal cancer excision, the shortfall was − 28,2% (− 902 procedures) in April, − 29.7% (− 938) in May, − 11.0% (− 318) in June, − 12.2% (− 421) in July, and − 1.6% (− 42) in August. For breast cancer, the greatest decrease was in May, − 38.0% (− 2604 procedures). The cumulative shortfall over the year came to 3505 surgical procedures, i.e. -4.5% despite greater activity in 2020 in the last months of the year.

For other cancer types, impacts on cancer excision are reported in Table 2.

Chemotherapy (Table 3)

Table 3.

Chemotherapy and radiotherapy activities.

January February March April May June July August September October November December Total
Chemotherapy − Stay and session
2019 261,746 232,029 246,942 260,052 257,065 232,361 268,008 251,344 245,514 277,457 240,063 248,137 3,020,718
2020 269,722 240,690 250,771 240,149 227,922 251,182 262,722 239,286 257,318 260,488 252,180 272,040 3,024,470
2021 251,887 246,226 278,241 776,354
Difference 2019/2020 7976 8661 3829  − 19,903  − 29,143 18,821  − 5286  − 12,058 11,804  − 16,969 12,117 23,903 3752
Percent 2019/2020 3.0 3.7 1.6  − 7.7  − 11.3 8.1  − 2.0  − 4.8 4.8  − 6.1 5.0 9.6 0.12
Difference 2019/2021  − 9859 14,197 31,299  − 
Percent 2019 − 2021  − 3.8 6.1 12.7  − 
Chemotherapy − Persons
2019 130,222 126,275 129,884 131,058 130,385 127,105 132,862 129,612 130,700 134,232 130,891 130,016 323,394
2020 135,370 132,347 133,626 125,052 128,920 132,364 134,565 131,316 135,563 137,184 137,370 139,049 330,581
2021 139,452 138,822 141,513 186,927
Difference 2019/2020 5148 6072 3742  − 6006  − 1465 5259 1703 1704 4863 2952 6479 9033 7187
Percent 2019/2020 4.0 4.8 2.9  − 4.6  − 1.1 4.1 1.3 1.3 3.7 2.2 4.9 6.9 2.22
Difference 2019/2021 9230 12,547 11,629  − 
Percent 2019 − 2021 7.1 9.9 9.0  − 
Radiotherapy − Inpatients
2019 18,251 17,825 18,393 18,511 18,202 17,556 19,271 17,947 17,795 19,074 17,334 17,182 114,930
2020 18,115 17,549 17,576 15,420 15,353 17,652 17,805 15,730 16,440 16,990 16,603 16,922 110,552
2021 17,012 17,504 18,775 36,250
Difference 2019/2020  − 136  − 276  − 817  − 3091  − 2849 96  − 1466  − 2217  − 1355  − 2084  − 731  − 260  − 4378
Percent 2019/2020  − 0.7  − 1.5  − 4.4  − 16.7  − 15.7 0.5  − 7.6  − 12.4  − 7.6  − 10.9  − 4.2  − 1.5  − 3.8
Difference 2019/2021  − 1239  − 321 382  − 
Percent 2019 − 2021  − 6.8  − 1.8 2.1  − 
Radiotherapy − outpatients
2019 17,944 16,652 17,340 17,308 17,105 16,563 18,352 15,967 16,567 17,780 16,191 16,678 108,979
2020 17,665 16,743 16,829 15,511 15,410 17,143 16,763 14,943 16,173 16,929 16,360 16,956 107,384
2021 16,410 15,622 15,001 32,161
Difference 2019/2020  − 279 91  − 511  − 1797  − 1695 580  − 1589  − 1024  − 394  − 851 169 278  − 1595
Percent 2019/2020  − 1.6 0.5  − 2.9  − 10.4  − 9.9 3.5  − 8.7  − 6.4  − 2.4  − 4.8 1.0 1.7  − 1.5
Difference 2019/2021  − 1534  − 1030  − 2339  − 
Percent 2019 − 2021  − 8.5  − 6.2  − 13.5  − 

Numbers of persons, stays and sessions observed are in [bold].

The number of chemotherapy sessions was slightly up in January, February and March (+ 1.6%, 3,829 sessions/admissions), down − 7.7% (− 19,903) in April, and − 11.3% (− 29,143) in May, and subsequently fluctuated depending on the month. The number of patients treated over the year increased by 2.2% (+ 7,187).

Radiotherapy (Table 3)

The number of patients receiving radiotherapy treatment dropped considerably both in the hospital sector and in private practice in April (− 16.7%, − 3091 patients, and − 10.4%, − 1797, respectively) and in May (− 15.7%, − 2849 and 9.9%, − 1695), and subsequently fluctuated depending on the month. Over the year, the decrease was 3.8% (− 4378 patients) in the hospital sector, and − 1.5% (− 1595) in private practice.

Discussion

Regardless of the type of activity (diagnosis, screening and excision), the impact of the first lockdown is roughly the same: a shortfall in March, which worsened in April, partial recovery in May. The activity in the months following the easing of lockdown restrictions failed to bridge the gap observed, with activity reaching a similar level to the previous year.

Over the last months of the year, greater activity was observed in 2020 for mammograms, prostate biopsies, and excisions as a whole. Nevertheless, for oesophageal cancers and ENT cancers, the activity remained lower in 2020 compared to 2019 even at year end. Unlike the first lockdown, the restrictions applied from the end of October 2020 were not associated with a significant decrease in activity, suggesting a safeguarding of cancer care activity and the application of the guidelines issued following the first lockdown.

As such, over 2020, a substantial shortfall in activity remains, in terms of diagnosis, screening, and excisions. For the organised colorectal cancer screening programme, the results are deceptive, as the slight difference needs to be put into perspective with the disruptions in the supply of tests in 2019.

The main strength of this study is that it allowed regular monitoring of the health situation in cancer care based on exhaustive data, relating to prevention, screening, diagnosis, and care. The SNDS contains data from non-hospital settings and hospital data for the entire population. Although this medico-administrative database contains no clinical data, it enables effective monitoring of care activity. A further advantage of this study is that it covered a population of 67 million inhabitants, and included all patients regardless of their social or economic status or insurance scheme. Due to its exhaustive nature, it made it possible to monitor the health impact of the different lockdown periods, and of the different measures following the first lockdown and applied during subsequent months.

A number of lessons can be taken from these scorecards. During the first lockdown in March 2020, a substantial decline in activity as a whole was observed, both for the diagnostic and treatment activity. In the case of the latter, a lag occurred with a slight decrease in activity during March, but a later recovery came in June after the lockdown was lifted in May. This particularly reflects the impact of the health crisis on scheduled activity (particularly surgical activity). Furthermore, the shortfall in activity was not bridged in the months that followed the lifting of the lockdown. A further lesson relates to the lockdown initiated in November 2020. Unlike the first lockdown, the directives given to safeguard diagnostic and therapeutic activities in cancer care appear to have been followed, thus limiting the impact of this further lockdown period.

The impact of the health crisis is observed in many countries. For example, in the USA, several studies on medico-administrative databases report decreases of over 75% in breast, colorectal and cervical cancer screening activity during lockdown12,18,19. Similar findings are observed in Europe, with treatment-related activity also being impacted, with changes in practices and times to complete treatments2025.

One limitation stems from the three-month time-frame for obtaining data, but scorecard processing is nonetheless not affected. Indeed, even though the aim is to enable accurate steering of the health crisis, these scorecards provide a good overview of the situation. This limitation is explained by the need to obtain exhaustive data. In the context of COVID-19, it is necessary to have daily monitoring of all hospitalisations due to COVID-19 in order to adapt health measures on a day-by-day basis. As regards cancer care activity monitoring, it is necessary to differentiate between a decrease in activity due to underreporting (lack of exhaustive data) and an actual decrease in activity. Furthermore, the measures adopted by the authorities on a national and local level and by healthcare professionals are measures to be applied over subsequent weeks or even months and do not require day-to-day steering.

Following on from these scorecards, further processing may be conducted to study the impact on a department or regional level. This could be compared to the spread of the virus in these areas. Besides these scorecards which do not allow monitoring of diagnostic and treatment activity for each individual, it would be beneficial to conduct follow-up studies on cancer patients’ care pathways. It will then be possible to estimate times to treatment, the potential transfer of activity particularly from surgery to chemotherapy and hormone therapy, or the forgoing of care. The number of chemotherapy inpatients is slightly higher in 2020, and there may be a carryover to oral therapies in non-hospital settings. The number of patients treated with radiotherapy is also lower, suggesting that the decrease in the number of sessions is not only due to the higher frequency of hypofractionated regimens. Follow-up studies will also help assess the impact of the current health crisis on recurrence and survival rates.

The primary causes identified during the first wave are the closure of so-called “non-emergency” medical activities, and low uptake of care, whether from primary care professionals or from cancer care professionals. According to a study by the Observatory on non-uptake of social rights and public services (Odenore) and the French national health insurance fund26, 60% of those surveyed report having decided not to receive one care that they needed at least once during the first lockdown. Similarly, 50% are of the view that not receiving care worsened their health problems.

It is difficult to obtain an accurate idea of the proportion attributable to these different causes of a shortfall in activity during the first wave and over time. Nevertheless, besides the waiting lists generated by the reduction in activity, non-uptake of care is likely to continue despite increased screening, diagnostic, and treatment capacities.

Conclusion

Monitoring cancer care activity using SNDS data makes it possible to assess the impact of COVID-19 and the resulting health measures, particularly in the field of cancer care. The impact was greater in the first lockdown; however, despite the health measures adopted, the gap in activity does not appear to have been bridged. In some time, further studies will make it possible to assess the impact of COVID-19 not only on care pathways, recurrence, after-effects, and survival, but also on the forgoing of care.

Acknowledgements

The authors would like to thank the French national health insurance fund (CNAM) and the French agency for information on hospital management for providing the data.

Author contributions

C.L.B.B.: conceptualization, methodology, writing, supervision M.R.: software, data curation, review I.K.: software, data curation, review E.M.: software, data curation, review J.A.S.: validation, review E.H.B.: validation, review J.B.M.: validation, review P.J.B.: conceptualization, methodology, writing, supervision.

Funding

The study was self-funded by the French national cancer institute.

Data availability

According to the European general data privacy regulation, an interested party interested in acceding data has to obtain an authorization from the French national ethic committee (CESREES) and the Cnil (French data protection authority) (contact: French national cancer institute).

Competing interests

The authors declare no competing interests.

Footnotes

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

According to the European general data privacy regulation, an interested party interested in acceding data has to obtain an authorization from the French national ethic committee (CESREES) and the Cnil (French data protection authority) (contact: French national cancer institute).


Articles from Scientific Reports are provided here courtesy of Nature Publishing Group

RESOURCES